190 related articles for article (PubMed ID: 37343519)
21. Efficacy and safety of fezolinetant, a neurokinin-3 antagonist, in treating vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis.
Rahman UA; Kashif TB; Usman M; Rana M; Hasanain M; Anjum MU; Cheema HA; Jaffar H; Bhattarai P
Medicine (Baltimore); 2023 Dec; 102(50):e36592. PubMed ID: 38115258
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Fezolinetant for the Treatment of Menopause-Associated Vasomotor Symptoms: A Meta-analysis.
Bonga KN; Mishra A; Maiti R; Padhy BM; Meher BR; Srinivasan A
Obstet Gynecol; 2024 Mar; 143(3):393-402. PubMed ID: 38227939
[TBL] [Abstract][Full Text] [Related]
23. Neurokinin 3 Receptor Antagonism: A Novel Treatment for Menopausal Hot Flushes.
Modi M; Dhillo WS
Neuroendocrinology; 2019; 109(3):242-248. PubMed ID: 30504731
[TBL] [Abstract][Full Text] [Related]
24. Finding SKYLIGHT for all: fezolinetant efficacy for vasomotor symptoms in subpopulations.
Reed SD
Menopause; 2024 Apr; 31(4):245-246. PubMed ID: 38517209
[No Abstract] [Full Text] [Related]
25. Neurokinin 1/3 receptor antagonists for menopausal women: A current systematic review and insights into the investigational non-hormonal therapy.
Hassan F; Saleem A; Samuel SS; Sarfraz Z; Sarfraz A; Sarfraz M; Kc M
Medicine (Baltimore); 2023 Jun; 102(23):e33978. PubMed ID: 37335635
[TBL] [Abstract][Full Text] [Related]
26. Neurokinin 3 receptor antagonists - prime time?
Prague JK
Climacteric; 2021 Feb; 24(1):25-31. PubMed ID: 33135940
[TBL] [Abstract][Full Text] [Related]
27. Neurokinin 3 Receptor Antagonists Compared With Serotonin Norepinephrine Reuptake Inhibitors for Non-Hormonal Treatment of Menopausal Hot Flushes: A Systematic Qualitative Review.
Menown SJ; Tello JA
Adv Ther; 2021 Oct; 38(10):5025-5045. PubMed ID: 34514552
[TBL] [Abstract][Full Text] [Related]
28. Neurokinin 3 Receptor Antagonism Reveals Roles for Neurokinin B in the Regulation of Gonadotropin Secretion and Hot Flashes in Postmenopausal Women.
Skorupskaite K; George JT; Veldhuis JD; Millar RP; Anderson RA
Neuroendocrinology; 2018; 106(2):148-157. PubMed ID: 28380486
[TBL] [Abstract][Full Text] [Related]
29. FDA approved fezolinetant (Veozah): a critical evaluation of its efficacy and safety for menopausal vasomotor symptoms, calling for prospective research.
Rani P; Zehra D; Mansoor M; Rani P
Arch Womens Ment Health; 2024 Mar; ():. PubMed ID: 38478035
[TBL] [Abstract][Full Text] [Related]
30. Fezolinetant (Veozah) for the Treatment of Menopause Symptoms.
Crespo C; Erlich D
Am Fam Physician; 2024 Mar; 109(3):273-274. PubMed ID: 38574221
[No Abstract] [Full Text] [Related]
31. The neurokinin B pathway in the treatment of menopausal hot flushes.
Anderson RA; Skorupskaite K; Sassarini J
Climacteric; 2019 Feb; 22(1):51-54. PubMed ID: 30572747
[TBL] [Abstract][Full Text] [Related]
32. Neurokinin B and Neurokinin-3 Receptor Signaling: Promising Developments in the Management of Menopausal Hot Flushes.
Modi M; Dhillo WS
Semin Reprod Med; 2019 May; 37(3):125-130. PubMed ID: 31869840
[TBL] [Abstract][Full Text] [Related]
33. Fezolinetant: A New Nonhormonal Treatment for Vasomotor Symptoms.
Onge ES; Phillips B; Miller L
J Pharm Technol; 2023 Dec; 39(6):291-297. PubMed ID: 37974591
[No Abstract] [Full Text] [Related]
34. Neurokinin 3 receptor antagonism - the magic bullet for hot flushes?
Prague JK; Dhillo WS
Climacteric; 2017 Dec; 20(6):505-509. PubMed ID: 29040006
[TBL] [Abstract][Full Text] [Related]
35. More promising news (mostly) on manipulating neurokinin B activity as a nonhormonal treatment of hot flashes.
Reame NK
Menopause; 2020 Apr; 27(4):375-376. PubMed ID: 32132443
[No Abstract] [Full Text] [Related]
36. Neurokinin 3 receptor antagonism - Is this the end of HRT?
Simpson P; Currie H; Morris E
Post Reprod Health; 2018 Jun; 24(2):61-62. PubMed ID: 29925302
[No Abstract] [Full Text] [Related]
37. Fezolinetant: A Potential Treatment for Moderate to Severe Vasomotor Symptoms of Menopause.
DePree B
touchREV Endocrinol; 2023 Nov; 19(2):69-72. PubMed ID: 38187079
[TBL] [Abstract][Full Text] [Related]
38. Managing vasomotor symptoms in women after cancer.
Pinkerton JV; Santen RJ
Climacteric; 2019 Dec; 22(6):544-552. PubMed ID: 31081391
[TBL] [Abstract][Full Text] [Related]
39. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial.
Prague JK; Roberts RE; Comninos AN; Clarke S; Jayasena CN; Nash Z; Doyle C; Papadopoulou DA; Bloom SR; Mohideen P; Panay N; Hunter MS; Veldhuis JD; Webber LC; Huson L; Dhillo WS
Lancet; 2017 May; 389(10081):1809-1820. PubMed ID: 28385352
[TBL] [Abstract][Full Text] [Related]
40. Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.
Neal-Perry G; Cano A; Lederman S; Nappi RE; Santoro N; Wolfman W; English M; Franklin C; Valluri U; Ottery FD
Obstet Gynecol; 2023 Apr; 141(4):737-747. PubMed ID: 36897180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
